LIVIVO - Search results -

Search results

Result 1 - 10 of total 36

Search options

Book ; Thesis: Modulation thrombzytärer und endothelialer Funktionen durch Diphydropyridin-Calciumantagonisten

Berkels, Reinhard

2001

Author's details	vorgelegt von Reinhard Berkels
Language	German
Size	44 [74] Bl. : Ill., graph. Darst.
Publishing country	Germany
Document type	Book ; Thesis
Thesis / German Habilitation thesis	Köln, Univ., Habil.-Schr., 2001
HBZ-ID	HT013214668
Database	Catalogue ZB MED Medicine, Health

In stock of ZB MED Cologne/Königswinter

Shelf mark	Loan status	Location
2001 E 3719	order for loan	Magazin

Order via subito

This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

Details ▾
- See ZB MED holdings
- Order with fees

Book ; Thesis: Untersuchungen zum thrombozytären L-Arginin-NO-Metabolismus und dessen Modulation durch den Calciumantagonisten Nifedipin

Berkels, Reinhard

1996

Author's details	vorgelegt von Reinhard Berkels
Language	German
Size	VIII, 107 S. : Ill., graph. Darst.
Document type	Book ; Thesis
Thesis / German Habilitation thesis	Köln, Univ., Diss., 1996
HBZ-ID	HT007173572
Database	Catalogue ZB MED Medicine, Health

In stock of ZB MED Cologne/Königswinter

Shelf mark	Loan status	Location
96 D 1825	order for loan	Magazin

Order via subito

Details ▾
- See ZB MED holdings
- Order with fees

Book: Kalziumantagonisten-Handbuch

Berkels, Reinhard / Bönner, Gerd

Pharmakologie und Klinik ; mit 42 Tabellen

2002

Author's details	hrsg. von G. Bönner ... Mit Beitr. von R. Berkels
Keywords	Calciumantagonist
Subject	Calciumblocker ; Kalziumantagonist ; Calcium ; Ca-Antagonist ; Calciumkanalblocker
Language	German
Size	XII, 548 S. : Ill., graph. Darst.
Publisher	Schattauer
Publishing place	Stuttgart u.a.
Publishing country	Germany
Document type	Book
HBZ-ID	HT013233300
ISBN	3-7945-1952-3 ; 978-3-7945-1952-1
Database	Catalogue ZB MED Medicine, Health

In stock of ZB MED Cologne/Königswinter

Shelf mark	Loan status	Location
2002 A 473	order for loan	Magazin

Order via subito

Details ▾
- See ZB MED holdings
- Order with fees

Article ; Online: Reduction of gastrointestinal symptoms in Parkinson's disease after a switch from oral therapy to rotigotine transdermal patch: a non-interventional prospective multicenter trial.

Woitalla, Dirk / Kassubek, Jan / Timmermann, Lars / Lauterbach, Thomas / Berkels, Reinhard / Grieger, Frank / Müller, Thomas

Parkinsonism & related disorders

2015 Volume 21, Issue 3, Page(s) 199–204

Abstract: Introduction: Gastrointestinal (GI) symptoms are common among patients with Parkinson's disease (PD), due to both the disease itself and anti-PD drugs. We hypothesized that transdermal drug administration may result in fewer GI problems. This ... ...

Abstract	Introduction: Gastrointestinal (GI) symptoms are common among patients with Parkinson's disease (PD), due to both the disease itself and anti-PD drugs. We hypothesized that transdermal drug administration may result in fewer GI problems. This prospective observational study (ClinicalTrials.gov: NCT01159691) investigated effect of switching to rotigotine transdermal patch from oral anti-PD medications in patients with PD and existing GI symptoms. Methods: Patients were enrolled if their physician was planning to switch them to rotigotine because of GI symptoms experienced while receiving oral anti-PD medications. Effectiveness assessments included a visual analog scale (VAS) measuring intensity of GI symptoms from 0 (no disorder) to 100 mm (extremely severe disorder), a questionnaire on the frequency and intensity of six individual GI complaints (heartburn, bloating, nausea, vomiting, abdominal pain, diarrhea), each rated 0-12 for a sum score of 0-72, and patient satisfaction regarding GI symptoms over approximately 6 weeks after switching. Results: Of 75 patients who received rotigotine, 58 had follow-up data available for final analysis. Intensity of GI complaints improved numerically on both the VAS (47.5 ± 24.4 mm [n = 65] at baseline, 19.7 ± 23.3 mm [n = 58] after around 6 weeks) and the sum score of GI complaints (11.2 ± 9.0 at baseline, 2.1 ± 4.4 [n = 58] after around 6 weeks). Fifty of 58 patients were "satisfied" or "very satisfied" regarding GI symptoms over around 6 weeks following switch to the patch. Conclusion: This study suggests that a switch from oral anti-PD medications to rotigotine transdermal patch may improve existing GI symptoms among patients with PD. Additional controlled studies are needed to confirm this finding.
MeSH term(s)	Administration, Oral ; Aged ; Aged, 80 and over ; Antiparkinson Agents/administration & dosage ; Female ; Follow-Up Studies ; Gastrointestinal Diseases/drug therapy ; Gastrointestinal Diseases/etiology ; Humans ; Male ; Middle Aged ; Pain Measurement ; Parkinson Disease/complications ; Parkinson Disease/drug therapy ; Patient Satisfaction ; Tetrahydronaphthalenes/administration & dosage ; Thiophenes/administration & dosage ; Transdermal Patch
Chemical Substances	Antiparkinson Agents ; Tetrahydronaphthalenes ; Thiophenes ; rotigotine (87T4T8BO2E)
Language	English
Publishing date	2015-03
Publishing country	England
Document type	Clinical Trial ; Journal Article ; Multicenter Study ; Observational Study ; Research Support, Non-U.S. Gov't
ZDB-ID	1311489-x
ISSN	1873-5126 ; 1353-8020
ISSN (online)	1873-5126
ISSN	1353-8020
DOI	10.1016/j.parkreldis.2014.11.024
Database	MEDical Literature Analysis and Retrieval System OnLINE

In stock of ZB MED Cologne/Königswinter

Zs.A 4553: Show issues			Location: Je nach Verfügbarkeit (siehe Angabe bei Bestand) bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular Jg. 1995 - 2021: Lesesall (2.OG) ab Jg. 2022: Lesesaal (EG)
Zs.MO 420: Show issues

Order via subito

Details ▾
- See ZB MED holdings
- Order with fees

Book ; Thesis: Untersuchungen zum thrombozytären L-Arginin-NO-Metabolismus und dessen Modulation durch den Calciumantagonisten Nifedipin

Berkels, Reinhard

1996

Author's details	vorgelegt von Reinhard Berkels
Language	German
Size	VIII, 107 S, Ill., graph. Darst, 21 cm
Document type	Book ; Thesis
Thesis / German Habilitation thesis	Univ., Diss.--Köln, 1996
Database	Library catalogue of the German National Library of Science and Technology (TIB), Hannover

Inter-library loan at ZB MED

Your chosen title can be delivered directly to ZB MED Cologne location if you are registered as a user at ZB MED Cologne.

Details ▾

Book ; Thesis: Untersuchungen zum thrombozytären L-Arginin-NO-Metabolismus und dessen Modulation durch den Calciumantagonisten Nifedipin

Berkels, Reinhard

1996

Author's details	vorgelegt von Reinhard Berkels
Language	German
Size	VIII, 107 S, Ill., graph. Darst, 21 cm
Document type	Book ; Thesis
Thesis / German Habilitation thesis	Univ., Diss.--Köln, 1996
Database	Former special subject collection: coastal and deep sea fishing

Inter-library loan at ZB MED

Your chosen title can be delivered directly to ZB MED Cologne location if you are registered as a user at ZB MED Cologne.

Details ▾

Article ; Online: Upregulation and activation of eNOS by resveratrol.

Taubert, Dirk / Berkels, Reinhard

Circulation

2003 Volume 107, Issue 11, Page(s) e78–9; author reply e78–9

MeSH term(s)	Antioxidants/pharmacology ; Cardiotonic Agents/pharmacology ; Enzyme Activation ; Nitric Oxide Synthase/biosynthesis ; Nitric Oxide Synthase/metabolism ; Nitric Oxide Synthase Type III ; Resveratrol ; Stilbenes/pharmacokinetics ; Stilbenes/pharmacology ; Up-Regulation ; Wine
Chemical Substances	Antioxidants ; Cardiotonic Agents ; Stilbenes ; Nitric Oxide Synthase (EC 1.14.13.39) ; Nitric Oxide Synthase Type III (EC 1.14.13.39) ; Resveratrol (Q369O8926L)
Language	English
Publishing date	2003-03-25
Publishing country	United States
Document type	Letter ; Comment
ZDB-ID	80099-5
ISSN	1524-4539 ; 0009-7322 ; 0069-4193 ; 0065-8499
ISSN (online)	1524-4539
ISSN	0009-7322 ; 0069-4193 ; 0065-8499
DOI	10.1161/01.cir.0000060819.46705.ee
Database	MEDical Literature Analysis and Retrieval System OnLINE

In stock of ZB MED Cologne/Königswinter

Ui IV Zs.60: Show issues

Location:
Je nach Verfügbarkeit (siehe Angabe bei Bestand)
bis Jg. 2021: Bestellungen von Artikeln über das Online-Bestellformular
ab Jg. 2022: Lesesaal (EG)

Order via subito

Details ▾
- See ZB MED holdings
- Order with fees

Article ; Online: Management of augmentation of restless legs syndrome with rotigotine: a 1-year observational study.

Trenkwalder, Claudia / Canelo, Monica / Lang, Michael / Schroeder, Hanna / Kelling, Daniela / Berkels, Reinhard / Schollmayer, Erwin / Heidbrede, Tanja / Benes, Heike

Sleep medicine

2015 Volume 30, Page(s) 257–265

Abstract: Aim: The aim of this study is to assess the effect of switching to rotigotine transdermal patch on severity of restless legs syndrome (RLS) in patients who experienced acute augmentation with previous oral dopaminergics.: Methods: In this 13-month ... ...

Abstract	Aim: The aim of this study is to assess the effect of switching to rotigotine transdermal patch on severity of restless legs syndrome (RLS) in patients who experienced acute augmentation with previous oral dopaminergics. Methods: In this 13-month observational study, adults with moderate-to-severe RLS and augmentation were switched to rotigotine per the physician's independent decision. Assessments included Clinical Global Impression severity score (CGI-1); (primary), treatment regimen for switching (secondary), RLS-6, International RLS Study Group Rating Scale (IRLS), and augmentation severity rating scale (ASRS). Results: A total of 99 patients received rotigotine, of whom 46 completed observational period, and 43 were assessed for effectiveness. A total of 5 patients switched to rotigotine after a >1-day drug holiday, 23 switched overnight, 9 had an overlapping switch, and 6 received ongoing oral dopaminergics with rotigotine for ≥28 days. Of the 99 patients, 57 took concomitant RLS medications (excluding switching medications) on at least 1 day. At the final visit, median change in CGI-1 (Hodges-Lehman estimate [95% CI]) was -2.0 (-2.5, -1.50); 37 of the 43 patients improved by ≥1 CGI-1 category, and 16 of 43 were responders (≥50% improvement). RLS-6 and IRLS scores also improved. Patients had median ASRS of 0 at the final visit indicating "no worsening/occurrence of augmentation." ASRS item 1 showed a shift in mean time of symptom onset (24-h clock) from 12:38 (baseline) to 18:25 (final visit). Most common reasons for withdrawal of rotigotine were adverse events (26 patients) and lack of efficacy (14 patients). Conclusions: Switching from oral therapies to rotigotine was effective in improving RLS symptoms in 37 of the 43 patients (from the original population of 99 patients) who remained in the study over 13 months. Clinical trial registration: ClinicalTrials.govNCT01386944.
MeSH term(s)	Adult ; Aged ; Dopamine Agonists/administration & dosage ; Dopamine Agonists/adverse effects ; Female ; Humans ; Male ; Middle Aged ; Restless Legs Syndrome/drug therapy ; Tetrahydronaphthalenes/administration & dosage ; Tetrahydronaphthalenes/adverse effects ; Thiophenes/administration & dosage ; Thiophenes/adverse effects ; Transdermal Patch
Chemical Substances	Dopamine Agonists ; Tetrahydronaphthalenes ; Thiophenes ; rotigotine (87T4T8BO2E)
Language	English
Publishing date	2015-11-11
Publishing country	Netherlands
Document type	Journal Article ; Observational Study ; Research Support, Non-U.S. Gov't
ZDB-ID	2012041-2
ISSN	1878-5506 ; 1389-9457
ISSN (online)	1878-5506
ISSN	1389-9457
DOI	10.1016/j.sleep.2015.10.006
Database	MEDical Literature Analysis and Retrieval System OnLINE

In stock of ZB MED Cologne/Königswinter

Zs.A 5315: Show issues			Location: Je nach Verfügbarkeit (siehe Angabe bei Bestand) bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular Jg. 1995 - 2021: Lesesall (2.OG) ab Jg. 2022: Lesesaal (EG)
Zs.MO 635: Show issues

Order via subito

Details ▾
- See ZB MED holdings
- Order with fees

Article ; Online: Caregivers' and physicians' attitudes to rotigotine transdermal patch versus oral Parkinson's disease medication: an observational study.

Sieb, Jörn Peter / Themann, Peter / Warnecke, Tobias / Lauterbach, Thomas / Berkels, Reinhard / Grieger, Frank / Lorenzl, Stefan

Current medical research and opinion

2015 Volume 31, Issue 5, Page(s) 967–974

Abstract: Objective: To provide real-world data on caregiver and physician perceptions of the advantages and disadvantages of rotigotine transdermal patch (Neupro * ) versus oral Parkinson's Disease (PD) medication.: Methods: Cross-sectional, non- ... ...

Abstract	Objective: To provide real-world data on caregiver and physician perceptions of the advantages and disadvantages of rotigotine transdermal patch (Neupro * ) versus oral Parkinson's Disease (PD) medication. Methods: Cross-sectional, non-interventional study in routine clinical practice in Germany (NCT01330290). Patients had PD with documented need for care, and had received rotigotine transdermal patch as add-on to oral PD treatment for ≥1 month. Caregivers/nurses and physicians assessed rotigotine transdermal patch versus oral PD medications using questionnaires. Specific questions regarding the possible benefits of transdermal application were asked and comprised questions on: swallowing dysfunction, nausea/vomiting, monitoring therapy, once daily application, application independently from meals, application to sleeping patients, caregiving efforts (caregivers only) and clinical aspects (physicians only). Each question was assessed on a 5 point scale ranging from -2 (major disadvantage) to 2 (major advantage) compared with oral treatment. Primary outcomes were mean total scores of all questions for caregivers/nurses and physicians who provided responses for ≥4 questions. As there are no validated tools to assess physician/caregiver preference in the PD setting, there is no reference against which the current findings can be compared; this study serves to pilot the questionnaires. Results: Questionnaire responses from 128 caregivers/nurses and 41 physicians were documented for 147 patients. One hundred (68%) patients had a caregiving family member; 40 (27%) were cared for by a nurse. Mean PD duration was 8.2 (SD 6.3) years; 136 (93%) patients were taking levodopa. Mean total score of caregivers'/nurses' questionnaires was 1.32 (SD 0.67) and of physicians' questionnaires was 1.46 (0.32) indicating a perceived advantage of rotigotine transdermal patch over oral PD therapy. Mean scores for individual questions were in the range 1.03-1.54 for caregivers/nurses and 1.15-1.87 for physicians. When given a choice about rationale to prescribe, physicians cited pharmaceutical form (patch) in 139 (95%) cases and active agent (rotigotine) in 89 (61%) cases. Conclusion: Caregivers/nurses and physicians perceived advantages with rotigotine transdermal patch compared to an oral PD medication as add-on therapy in patients with PD; advantages were observed in aspects of medical treatment as well as in everyday situations of caregiving of PD patients.
MeSH term(s)	Administration, Cutaneous ; Administration, Oral ; Adolescent ; Adult ; Aged ; Aged, 80 and over ; Caregivers/statistics & numerical data ; Cross-Sectional Studies ; Dopamine Agonists/administration & dosage ; Dopamine Agonists/therapeutic use ; Female ; Germany ; Humans ; Levodopa/therapeutic use ; Male ; Middle Aged ; Parkinson Disease/drug therapy ; Physicians/statistics & numerical data ; Pilot Projects ; Surveys and Questionnaires ; Tetrahydronaphthalenes/administration & dosage ; Tetrahydronaphthalenes/therapeutic use ; Thiophenes/administration & dosage ; Thiophenes/therapeutic use ; Transdermal Patch ; Young Adult
Chemical Substances	Dopamine Agonists ; Tetrahydronaphthalenes ; Thiophenes ; Levodopa (46627O600J) ; rotigotine (87T4T8BO2E)
Language	English
Publishing date	2015-05
Publishing country	England
Document type	Clinical Trial ; Comparative Study ; Journal Article ; Multicenter Study ; Research Support, Non-U.S. Gov't
ZDB-ID	80296-7
ISSN	1473-4877 ; 0300-7995
ISSN (online)	1473-4877
ISSN	0300-7995
DOI	10.1185/03007995.2015.1030376
Database	MEDical Literature Analysis and Retrieval System OnLINE

Full text online

Accessible to users with ZB MED library card

In stock of ZB MED Cologne/Königswinter

Zs.A 955: Show issues

Location:
Je nach Verfügbarkeit (siehe Angabe bei Bestand)
bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular
Jg. 1995 - 2021: Lesesall (1.OG)
ab Jg. 2022: Lesesaal (EG)

Order via subito

Details ▾

Article: The in vitro receptor profile of rotigotine: a new agent for the treatment of Parkinson's disease.

Scheller, Dieter / Ullmer, Christoph / Berkels, Reinhard / Gwarek, Mirella / Lübbert, Hermann

Naunyn-Schmiedeberg's archives of pharmacology

2008 Volume 379, Issue 1, Page(s) 73–86

Abstract: Rotigotine (Neupro) is a non-ergoline dopamine agonist developed for the once daily treatment of Parkinson's disease (PD) using a transdermal delivery system (patch) which provides patients with the drug continuously over 24 h. To fully understand the ... ...

Abstract	Rotigotine (Neupro) is a non-ergoline dopamine agonist developed for the once daily treatment of Parkinson's disease (PD) using a transdermal delivery system (patch) which provides patients with the drug continuously over 24 h. To fully understand the pharmacological actions of rotigotine, the present study determined its extended receptor profile. In standard binding assays, rotigotine demonstrated the highest affinity for dopamine receptors, particularly the dopamine D3 receptor (Ki=0.71 nM) with its affinities to other dopamine receptors being (Ki in nM): D4.2 (3.9), D4.7 (5.9), D5 (5.4), D2 (13.5), D4.4 (15), and D1 (83). Significant affinities were also demonstrated at alpha-adrenergic (alpha2B, Ki=27 nM) and serotonin receptors (5-HT1A Ki=30 nM). In newly developed reporter-gene assays for determination of functional activity, rotigotine behaved as a full agonist at dopamine receptors (rank order: D3>D2L>D1=D5>D4.4) with potencies 2,600 and 53 times higher than dopamine at dopamine D3 and D2L receptors, respectively. At alpha-adrenergic sites, rotigotine acted as an antagonist on alpha2B receptors. At serotonergic sites, rotigotine had a weak but significant agonistic activity at 5-HT1A receptors and a minor or nonexistent activity at other serotonin receptors. Thus, in respect to PD, rotigotine can be characterized as a specific dopamine receptor agonist with a preference for the D3 receptor over D2 and D1 receptors. In addition, it exhibits interaction with D4 and D5 receptors, the role of which in relation to PD is not clear yet. Among non-dopaminergic sites, rotigotine shows relevant affinity to only 5-HT1A and alpha2B receptors. Further studies are necessary to investigate the contribution of the different receptor subtypes to the efficacy of rotigotine in Parkinson's disease and possible other indications such as restless legs syndrome.
MeSH term(s)	Animals ; Antiparkinson Agents/pharmacology ; Binding, Competitive ; CHO Cells ; Cricetinae ; Cricetulus ; Dopamine Agonists/pharmacology ; Female ; Humans ; Receptors, Adrenergic/metabolism ; Receptors, Dopamine D3/metabolism ; Receptors, Dopamine D4/metabolism ; Receptors, Serotonin/metabolism ; Tetrahydronaphthalenes/pharmacology ; Thiophenes/pharmacology
Chemical Substances	Antiparkinson Agents ; Dopamine Agonists ; Receptors, Adrenergic ; Receptors, Dopamine D3 ; Receptors, Serotonin ; Tetrahydronaphthalenes ; Thiophenes ; Receptors, Dopamine D4 (137750-34-6) ; rotigotine (87T4T8BO2E)
Language	English
Publishing date	2008-08-14
Publishing country	Germany
Document type	Journal Article
ZDB-ID	121471-8
ISSN	1432-1912 ; 0028-1298
ISSN (online)	1432-1912
ISSN	0028-1298
DOI	10.1007/s00210-008-0341-4
Database	MEDical Literature Analysis and Retrieval System OnLINE

Full text online

Accessible to users with ZB MED library card

In stock of ZB MED Cologne/Königswinter

Ud II Zs.5: Show issues

Location:
Je nach Verfügbarkeit (siehe Angabe bei Bestand)
bis Jg. 2021: Bestellungen von Artikeln über das Online-Bestellformular
ab Jg. 2022: Lesesaal (EG)

Order via subito

Details ▾

To top

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito

More links

Kategorien

Inter-library loan at ZB MED

More links

Kategorien

Inter-library loan at ZB MED

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito

Full text online

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito

Full text online

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito